Drug name - Mycapssa
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265812 | AMRYT | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(6 years from now) | |
| US9566246 | AMRYT | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(6 years from now) | |
| US8329198 | AMRYT | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(6 years from now) | |
| US8535695 | AMRYT | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(6 years from now) | |
| US11052126 | AMRYT | Method of treating diseases |
Feb, 2036
(13 years from now) | |
| US10695397 | AMRYT | Method of treating diseases |
Feb, 2036
(13 years from now) | |
| US10238709 | AMRYT | Method of treating diseases |
Feb, 2036
(13 years from now) | |
| US11141457 | AMRYT | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(18 years from now) | |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel
Dosage: CAPSULE, DELAYED RELEASE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | CAPSULE, DELAYED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.